Ipca Laboratories on Wednesday reported a 24.15 per cent rise in consolidated net profit at Rs 197.54 crore for the quarter ended on December 31, 2019, on account of robust sales.The company had posted a net profit of Rs 159.11 crore for the corresponding period of previous fiscal, Ipca Laboratories said in a filing to the BSE.

Total income also rose to Rs 1,230.99 crore for the quarter under consideration as against Rs 1,019.48 crore in the year-ago period.

The company’s board has declared an interim dividend of Rs 5 per share, Ipca Laboratories said. Shares of Ipca Laboratories were trading at Rs 1,270 per scrip on the BSE, up 1.78 per cent over the previous close.

For more than 60 years, Ipca has been partnering healthcare globally in over 120 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.

Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments, one of the world's largest manufacturers and suppliers of over a dozen APIs.Produced right from the basic stage at manufacturing facilities inspected by the world's most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.

Ipca is also a therapy leader in India for anti-malarials with a market share of over 34% with a fast expanding presence in the international market as well. We also lead in DMARDs (Disease-Modifying Anti-Rheumatic Drugs) treatment for rheumatoid arthritis. We have leading brands in 5 therapeutic areas, with 3 of our branded formulations being ranked among the Top-300 Indian brands by ORG-IMS. Ipca was awarded as 'Among the 100 Best Companies to Work in India 2010' in a study conducted by Great Place to Work® - India in joint collaboration with The Economic Times.